Cargando…
Heterologous Vector—mRNA Based SARS-CoV-2 Vaccination Strategy Appears Superior to a Homologous Vector—Based Vaccination Scheme in German Healthcare Workers Regarding Humoral SARS-CoV-2 Response Indicating a High Boosting Effect by mRNA Vaccines
Background: Longitudinal humoral SARS-CoV-2 (severe acute respiratory syndrome coronavirus type 2) immunity for up to 15 months due to vaccination, the efficacy of vaccination strategies (homologous, vector–vector versus heterologous, vector–mRNA), the influence of vaccination side effects, and the...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10054089/ https://www.ncbi.nlm.nih.gov/pubmed/36992285 http://dx.doi.org/10.3390/vaccines11030701 |
_version_ | 1785015571314638848 |
---|---|
author | Gerhards, Catharina Thiaucourt, Margot Hetjens, Michael Haselmann, Verena Neumaier, Michael Kittel, Maximilian |
author_facet | Gerhards, Catharina Thiaucourt, Margot Hetjens, Michael Haselmann, Verena Neumaier, Michael Kittel, Maximilian |
author_sort | Gerhards, Catharina |
collection | PubMed |
description | Background: Longitudinal humoral SARS-CoV-2 (severe acute respiratory syndrome coronavirus type 2) immunity for up to 15 months due to vaccination, the efficacy of vaccination strategies (homologous, vector–vector versus heterologous, vector–mRNA), the influence of vaccination side effects, and the infection rate in German healthcare workers need to be investigated. Methods: In this study, 103 individuals vaccinated against SARS-CoV-2 were enrolled to examine their anti-SARS-CoV-2 anti-N- and anti-RBD/S1-Ig levels. A total of 415 blood samples in lithium heparin tubes were prospectively obtained, and a structured survey regarding medical history, type of vaccine, and vaccination reactions was conducted. Results: All participants demonstrated a humoral immune response, among whom no values decreased below the positivity cutoff. Five to six months after the third vaccination, three participants showed anti-RBD/S1 antibodies of less than 1000 U/mL. We observed higher levels for heterologous mRNA-/vector-based combinations compared to pure vector-based vaccination after the second vaccination, which is harmonized after a third vaccination with the mRNA-vaccine only in both cohorts. The incidence of vaccine breakthrough in a highly exposed cohort was 60.3%. Conclusion: Sustained long-term humoral immunity was observed, indicating the superiority of a heterologous mRNA-/vector-based combination compared to pure vector-based vaccination. There was longevity of anti-RBD/S1 antibodies of at least 4 and up to 7 months without external stimulus. Regarding vaccination reactogenity, the occurrence of local symptoms as pain at the injection site was increased after the first mRNA application compared to the vector–vector cohort with a general decrease in adverse events at later vaccination time points. Overall, a correlation between the humoral vaccination response and vaccination side effects was not observed. Despite the high prevalence of vaccine breakthroughs, these only occurred in the later course of the study when more infectious variants, which are, however, associated with milder courses, were present. These results provide insights into vaccine-related serologic responses, and the study should be expanded using additional vaccine doses and novel variants in the future. |
format | Online Article Text |
id | pubmed-10054089 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-100540892023-03-30 Heterologous Vector—mRNA Based SARS-CoV-2 Vaccination Strategy Appears Superior to a Homologous Vector—Based Vaccination Scheme in German Healthcare Workers Regarding Humoral SARS-CoV-2 Response Indicating a High Boosting Effect by mRNA Vaccines Gerhards, Catharina Thiaucourt, Margot Hetjens, Michael Haselmann, Verena Neumaier, Michael Kittel, Maximilian Vaccines (Basel) Article Background: Longitudinal humoral SARS-CoV-2 (severe acute respiratory syndrome coronavirus type 2) immunity for up to 15 months due to vaccination, the efficacy of vaccination strategies (homologous, vector–vector versus heterologous, vector–mRNA), the influence of vaccination side effects, and the infection rate in German healthcare workers need to be investigated. Methods: In this study, 103 individuals vaccinated against SARS-CoV-2 were enrolled to examine their anti-SARS-CoV-2 anti-N- and anti-RBD/S1-Ig levels. A total of 415 blood samples in lithium heparin tubes were prospectively obtained, and a structured survey regarding medical history, type of vaccine, and vaccination reactions was conducted. Results: All participants demonstrated a humoral immune response, among whom no values decreased below the positivity cutoff. Five to six months after the third vaccination, three participants showed anti-RBD/S1 antibodies of less than 1000 U/mL. We observed higher levels for heterologous mRNA-/vector-based combinations compared to pure vector-based vaccination after the second vaccination, which is harmonized after a third vaccination with the mRNA-vaccine only in both cohorts. The incidence of vaccine breakthrough in a highly exposed cohort was 60.3%. Conclusion: Sustained long-term humoral immunity was observed, indicating the superiority of a heterologous mRNA-/vector-based combination compared to pure vector-based vaccination. There was longevity of anti-RBD/S1 antibodies of at least 4 and up to 7 months without external stimulus. Regarding vaccination reactogenity, the occurrence of local symptoms as pain at the injection site was increased after the first mRNA application compared to the vector–vector cohort with a general decrease in adverse events at later vaccination time points. Overall, a correlation between the humoral vaccination response and vaccination side effects was not observed. Despite the high prevalence of vaccine breakthroughs, these only occurred in the later course of the study when more infectious variants, which are, however, associated with milder courses, were present. These results provide insights into vaccine-related serologic responses, and the study should be expanded using additional vaccine doses and novel variants in the future. MDPI 2023-03-19 /pmc/articles/PMC10054089/ /pubmed/36992285 http://dx.doi.org/10.3390/vaccines11030701 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Gerhards, Catharina Thiaucourt, Margot Hetjens, Michael Haselmann, Verena Neumaier, Michael Kittel, Maximilian Heterologous Vector—mRNA Based SARS-CoV-2 Vaccination Strategy Appears Superior to a Homologous Vector—Based Vaccination Scheme in German Healthcare Workers Regarding Humoral SARS-CoV-2 Response Indicating a High Boosting Effect by mRNA Vaccines |
title | Heterologous Vector—mRNA Based SARS-CoV-2 Vaccination Strategy Appears Superior to a Homologous Vector—Based Vaccination Scheme in German Healthcare Workers Regarding Humoral SARS-CoV-2 Response Indicating a High Boosting Effect by mRNA Vaccines |
title_full | Heterologous Vector—mRNA Based SARS-CoV-2 Vaccination Strategy Appears Superior to a Homologous Vector—Based Vaccination Scheme in German Healthcare Workers Regarding Humoral SARS-CoV-2 Response Indicating a High Boosting Effect by mRNA Vaccines |
title_fullStr | Heterologous Vector—mRNA Based SARS-CoV-2 Vaccination Strategy Appears Superior to a Homologous Vector—Based Vaccination Scheme in German Healthcare Workers Regarding Humoral SARS-CoV-2 Response Indicating a High Boosting Effect by mRNA Vaccines |
title_full_unstemmed | Heterologous Vector—mRNA Based SARS-CoV-2 Vaccination Strategy Appears Superior to a Homologous Vector—Based Vaccination Scheme in German Healthcare Workers Regarding Humoral SARS-CoV-2 Response Indicating a High Boosting Effect by mRNA Vaccines |
title_short | Heterologous Vector—mRNA Based SARS-CoV-2 Vaccination Strategy Appears Superior to a Homologous Vector—Based Vaccination Scheme in German Healthcare Workers Regarding Humoral SARS-CoV-2 Response Indicating a High Boosting Effect by mRNA Vaccines |
title_sort | heterologous vector—mrna based sars-cov-2 vaccination strategy appears superior to a homologous vector—based vaccination scheme in german healthcare workers regarding humoral sars-cov-2 response indicating a high boosting effect by mrna vaccines |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10054089/ https://www.ncbi.nlm.nih.gov/pubmed/36992285 http://dx.doi.org/10.3390/vaccines11030701 |
work_keys_str_mv | AT gerhardscatharina heterologousvectormrnabasedsarscov2vaccinationstrategyappearssuperiortoahomologousvectorbasedvaccinationschemeingermanhealthcareworkersregardinghumoralsarscov2responseindicatingahighboostingeffectbymrnavaccines AT thiaucourtmargot heterologousvectormrnabasedsarscov2vaccinationstrategyappearssuperiortoahomologousvectorbasedvaccinationschemeingermanhealthcareworkersregardinghumoralsarscov2responseindicatingahighboostingeffectbymrnavaccines AT hetjensmichael heterologousvectormrnabasedsarscov2vaccinationstrategyappearssuperiortoahomologousvectorbasedvaccinationschemeingermanhealthcareworkersregardinghumoralsarscov2responseindicatingahighboostingeffectbymrnavaccines AT haselmannverena heterologousvectormrnabasedsarscov2vaccinationstrategyappearssuperiortoahomologousvectorbasedvaccinationschemeingermanhealthcareworkersregardinghumoralsarscov2responseindicatingahighboostingeffectbymrnavaccines AT neumaiermichael heterologousvectormrnabasedsarscov2vaccinationstrategyappearssuperiortoahomologousvectorbasedvaccinationschemeingermanhealthcareworkersregardinghumoralsarscov2responseindicatingahighboostingeffectbymrnavaccines AT kittelmaximilian heterologousvectormrnabasedsarscov2vaccinationstrategyappearssuperiortoahomologousvectorbasedvaccinationschemeingermanhealthcareworkersregardinghumoralsarscov2responseindicatingahighboostingeffectbymrnavaccines |